CRYSTAL-RAS-EXTENDED

NCT00154102 📎

Regimen

Experimental
Cetuximab + FOLFIRI
Control
FOLFIRI alone

Population

Metastatic CRC, 1L; subgroup re-analysis extending RAS mutation status beyond KRAS exon 2 to all KRAS/NRAS exons (subgroup re-analysis: RAS-extended).

Key finding

1L mCRC RAS-wt (pan-RAS, all KRAS/NRAS exons): cetuximab+FOLFIRI vs FOLFIRI: mOS 28.4 vs 20.2 mo (HR 0.69, 95% CI 0.54-0.88); mPFS 11.4 vs 8.4 mo (HR 0.56, 95% CI 0.41-0.76); RAS-mut subgroup: no benefit (mOS 17.7 vs 17.1 mo); extended RAS testing refined the predictive biomarker

Source: PMID 25605843

Timeline

    Guideline citations

    • NCCN Colon (p.35)
    • NCCN Rectal (p.46)